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Introduction-

ProblemBreast cancer is one of the most common and dangerous diseases
that affects women today.

In 1994, approximately 182,000 women were

diagnosed with breast cancer. (Sondik, 1994) This disease has become the
most common type of cancer among American women, accounting for more
than 30% of all cases. (American Cancer Society, 1994; Sondik, 1994) The
fact that the number of new cases each year has been gradually increasing
throughout much of the last decade is very ominous. (Sondik, 1994)

From

1970 to 1990, the incidence of breast cancer in the United States
•

increased over 21 %. (Sondik, 1994) (Figs. 1 & 2)
While the overall mortality rate increased only 3% from 1970 to
1990, 46,000 women still died of cancer in 1993. (Fig. 1)

The only cancer

more deadly was lung cancer. (American Cancer Society, 1994; Sondik,
1994)

In Iowa alone, 2,200 women died of the disease in 1994. (American

Cancer Society, 1994)

These statistics are reason for great concern.

As

explained by Edward J. Sondik, Ph.D, ·sased on the trends to date, there is
every reason to believe that the burden . of this disease will continue to
grow, not only in terms of absolute numbers of cases, but in incidence and

•

mortality rates." ( 1994)

This opinion of Dr. Sondik, is supported by recent
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•

estimates from the National Cancer Institute.

The risk that a woman will

develop breast cancer in her lifetime in now 1 in 8. (Sondik, 1994)
The increasing incidence rate, the increasing mortality rate, and the
sheer numbers of women that live with breast cancer each year make this
a very real and severe problem to the women of today and tomorrow.
However, women are not the only ones threatened by breast cancer.
Approximately 1,000 men are diagnosed with breast cancer each year, and
approximately 300 die of the disease.
All

of these factors

threatening condition.
•

demand

(American Cancer Society, 1994)

a greater understanding

of this life-

Learning more about breast cancer offers the

possibility of uncovering new techniques for earlier detection and more
effective treatment.
One treatment for breast cancer is mastectomy, or surgical removal
of the breast tissue.

The amount of tissue removed during a mastectomy

depends on the severity of the cancer.

For example, when an isolated

region of tumor cells is found, most often only that section of the breast
is removed . This process is known as lumpectomy.

A partial or segmental

mastectomy consists of removing approximately one-quarter of the breast
tissue.

•

A simple or total mastectomy involves removal of the entire

breast in which cancer has been found.

2

When cancer has spread from the

•

breast to the underarm lymph nodes and the lining over the chest muscles,
these tissues must be removed in a procedure known as a modified radical
mastectomy.

A radical mastectomy consists of removing the entire

breast, the underarm lymph nodes, and the chest muscles underneath the
breast.
Some women diagnosed with breast cancer have risk factors that
increase their chance of developing breast cancer again.
primary risk factors.

There are three

The first is a high family history of cancer.

For

example, some patients have a mother, sisters, aunts, or grandmothers
that either have or have had breast cancer.
•

Other types of cancer, such as

prostate, ovarian, and colo-rectal, confer higher risk of recurrence.

The

second risk factor contributing to a high chance of recurrence is age at
diagnosis.

The younger a woman is when she is diagnosed with breast

cancer, the higher the risk of developing cancer again.

The reasons for

this are many, but most important is the fact that women who are young
when they are diagnosed with cancer often have a genetic susceptibility
to breast cancer.

Serious tumor grade is the third risk factor.

The more

serious and developed a tumor is, the greater the chance that cancer will
redevelop after the tumor is treated.

•

Women who have been diagnosed with cancer in one breast often
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•

have a mastectomy to remove the tumor.

When a women also has one or

more of these risk factors, the treatment is often more aggressive.

In

many cases, a prophylactic mastectomy is performed in addition to the
mastectomy to remove the cancerous tissue.

A prophylactic mastectomy

is the removal of a non-cancerous breast in order to prevent tumor
development that can spread to other parts of the body.

This procedure

often causes a great deal of emotional suffering to a woman, even when
For this reason, as well as the fact that cancer

the surgery is elective.

may have never developed in the normal breast, the procedure is quite
considered quite aggressive.

•

Even so, many prophylactic mastectomies

are performed each year.
However, the need for such an aggressive precautionary procedure
has been questioned.

Despite the number of prophylactic mastectomies

performed, relatively little is known about the genetics of women who
have had the procedure.

For this reason, I conducted a study on the genetic

material of women who had prophylactic mastectomy surgery at the Mayo
Clinic in Rochester, Minnesota.

This project was part of a larger study

headed by Lynn Hartmann, M.D . and Robert Jenkins, M.D./Ph.D on the
clinical, psychosocial, and molecular aspects of women who have had
prophylactic mastectomies .

•

This thesis documents the severity of cancer
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•

in America today,

the effect of genetics on the development and

progression of cancer, and the results of my study on the genetic
characteristics of women who have had prophylactic mastectomy surgery.

Background-

What exactly is cancer?

It is a term that is heard every day in the

news, but the definition is somewhat vague to many.

In a nutshell, cancer

is a condition characterized by uncontrolled cell growth.

The American

Cancer Society defines cancer as, • ... a group of diseases characterized by
•

•

uncontrolled growth and spread of abnormal cells." (1994)

For some

reason, the cells of the body lose their ability to control their duplication.
Cell division,

is an entirely normal process

maintenance and growth.
problems develop.

required

for organism

However, when it is uncontrolled, many

Cell reproduction is controlled by a complex network of

systems that make up the cell cycle.

When a part, or parts of this system

break down, the result is uncontrolled cell replication.
of control occurs in a single cell.

Usually, this loss

When this single cell loses control of

its replication machinery, it keeps dividing and dividing, increasing in
number in an exponential fashion.

In a short period of time, there are

5
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•

•

many copies of the same cell.
anaplasia.

This loss of cell differentiation is termed

An abnormal growth made up of a collection of new cells is

called a neoplasm.

When the neoplasm is made up of anaplastic cells, it is

known as a tumor.
Tumors are quite complicated and developed biologically.

Since

tumor cells reproduce much faster than normal cells, they soon reach a
growth limit imposed by their environment, the body.

For example, cells

are supplied with oxygen, glucose, and other nutrients by blood vessels
known as capillaries.

When a concentrated growth of cells develops, as in

a tumor, the cells exhaust the nutrient supplies the blood vessels can
bring to that area.

To remedy this situation, tumor cells release factors

that promote blood vessel formation, a process known as angiogenesis.

In

this fashion, a tumor may continue its growth beyond normal limits.
As the severity of the tumor increases, it begins to branch out, a
process known as metastasis.

Cancer is a metastasizing tumor.

cancerous tumor is known as a malignant tumor.
cancerous is known as benign .

A

A tumor that is not

One of the ways a tumor branches out,

ironically, is by the vessels it helped form.

The tumor uses the blood

vessels it produced to carry tumor cells through the bloodstream to other
areas of the body .

Once established, these tumor cells keep dividing,

6

•

eventually forming another tumor.
satellite tumors.

These peripheral tumors are known as

As a result, by the time a person has cancer, they may

have a vast network of tumors throughout many portions of their body.
This is one of the reasons cancer is such a deadly disease -it can affect
many parts of a person's body.
to eliminate.

Also, metastasis makes cancer very tough

Even after a major tumor is removed, other tumors may still

be present or in the process of developing.

This is why early detection is

integral in a successful fight against cancer; detecting cancer early
increases the chances of eliminating the tumor cells before they have the
opportunity to spread .
•

Fortunately, most cancers are detected quite early.

(Fig. 8)
he fact th at cancer spreads very easily in the human body and is
resistant to treatment makes it very serious.

Perhaps most threatening

of is the frequency wiU1 wh ch cancer develops in the United States.

The

high prevalence of breast cancer in American women has already been
mentioned ; however, those numbers appear minor when compared to the
estimated 1,208,000 new cancer cases diagnosed in 1994. (American
Cancer Society, 1994)

This figure does not even include minor cancers

such as in situ carcinomas and basal and squamous cell skin cancers.

•

The

severity of cancer is strikingly evident in the 538 ,000 cancer deaths in

7

•

1994, amounting to 1400 people each day. (American Cancer Society,
1994)

Alarmingly, one in every five deaths in the .United States today is

due to cancer. (American Cancer Society, 1994)
Cancer can be caused by a variety of external or internal factors .
Examples of external factors are chemicals,

radiation,

and viruses.

Internal factors such as hormones, immune conditions, and inherited
mutations cari also cause the disease. (American Cancer Society, 1994)
One of the most common is the mutation of genetic material in a tumor
cell.

The genetic material of humans, as well as other organisms, is

Deoxyribose Nucleic Acid, or DNA.
•

•

DNA is composed of two strands that

form a right-handed double helix, like two spiral staircases
(Fig. 9a)

· entwined.

Each strand is composed of many nucleotide bases hooked

together in a chain pattern, end-to-end.

Each nucleotide base is made up

of three main parts: a sugar, a nucleic acid, and a triphosphate.
in DNA is deoxyribose, which is composed of five carbons.
add can be either adenine, cytosine, guanine, or thymine.

The sugar
The nucleic

The phosphate

group of one nucleotide acts to hold the bases together in strand
formation by attaching to the sugar of another nucleotide. (Fig. 9a)
The DNA of each cell is wound around histone proteins, forming
structures called nucleosomes .

These nucleosomes form a substance
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•

called chromatin, which makes up the basic genetic structures of each
cell, the chromosomes. (Fig. 9b)

Each chromosome has a central po~ion

called the centromere, which lies about one-third of the distance from one
of the ends.

This centromere divides two regions, called arms, of the

chromosome.

The short arm is referred to as the •pN arm, while the long

arm is referred to as the Nq" arm. (Fig. 9c)

All of the genetic information

of human cells is contained in 23 chromosomes. (Fig. 9d)
two copies of each of the 23 chromosomes .

Each cell has

On each of the 23 different

chromosomes, there is different information that makes each organism
unique.
•

•

The sections of each chromosome that make us unique are known

as genes.

Genes code for different polypeptides, or proteins.

Since there

are two copies of each chromosome, there are two copies of each gene in
each cell.

Each one of these copies is known as an allele.

How many

copies of each chromosome an organism has determines the phenotype, or
external characteristics, of an organism .

For example, in some cases,

individuals end up with three copies of chromosome 21, a situation known
as trisomy-21.

Trisomy-21 leads to the condition of Down's Syndrome.

How does DNA determine who we are?

It is based on two cellular

processes, known as transcription and translation.

Each base in the DNA

making up a chromosome is considered part of a three-base unit known as

9

a codon.

Each three base unit codes for one amino acid, the base unit of

protein.

Each amino acid is put together to make a substance called

messenger Ribonucleic Acid, or mRNA.
copied, into mRNA.

Thus, the DNA is transcribed, or

During translation, this copied mRNA is used as a

template to make proteins.

As mentioned earlier, each codon from mRNA

codes for an amino acid; the amino acids are then hooked together via
connections known as peptide bonds into polymers called polypeptides.
other words, polypeptides are just long chains of amino acids.

In

When a

polypeptide gets long enough, interactions between the amino acids give
the polypeptide a three-dimensional structure.

This three-dimensional

polypeptide is known as a protein.
Proteins do many different things in a cell.

Possibly their most

important role is acting as enzymes, which serve as catalysts for
biological reactions.

Catalysts allow reactions to occur much more

quickly than they would unaided.

Proteins also serve as transcription

factors and many other things.

These reactions make the various

processes of life possible, such as metabolism.

Therefore, life is made

possible by proteins, which owe their properties to the three-dimensional
structure made possible by the unique sequence of DNA.
As mentioned earlier, each organism carries slightly different DNA,

•
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thus, it has slightly different genes.

This is what makes us unique .

However, some DNA, most notably the DNA that codes for proteins, must
have a set sequence in order to produce viable proteins.

If the ·sequence is

lost or incorrect, the correct protein is not produced and the function it
serves is not fulfilled.

In diseases that are genetic, this is the problem.

Cancer is often a genetic disease.

Many types of cancer show genetic

irregularities in the DNA of the tumor cells.

The irregularities are

amazingly complex; there are many types of changes in each of the
different cancers.

In many cancers, more than one chromosome is altered,

or parts of many chromosomes may be lost. (Fig. 9d)

•

One method of measuring genetic instability, in terms of loss or gain
of an allele, is termed loss of heterozygosity.

If a person has two

identical copies of a gene, they are termed homozygous for that gene.

If a

person has two slightly different copies of a gene, they are termed
heterozygous for that gene.

In less of heterozygosity, or LOH studies,

normal DNA is compared to tumor DNA.
used for this method.

Only heterozygous DNA may be

This is due to the fact that one of the alleles of the

tumor DNA is compared to one of the alleles of the normal DNA. By using
this reference, it is possible to tell if one of the alleles has been lost, as
there will be a loss of intensity. (Fig. 10)

•
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Some researchers contend that

•

it is impossible to notice if there has been loss or gain, for this reason,
they prefer the term allelic imbalance (Al). (Borg et al., 1994)
Chromosome deletions have been noted in breast tumor DNA on
chromosomes 1p (Genuardi et al., 1989; Bieche et al., 1990), 1q (Merlo et
al., 1989), 3p (Ali et al., 1989; Chen et al., 1994), 4p (Dutriallaux et al.,
1990), 6q, Sp, 9p, 11p, 11q, 13q, 16q, 17p, 17q, and 18q. The great number
of chromosomal deletions makes elucidating the cause of cancer very
difficult.

Adding to this problem is the . difficulty in differentiating the

chromosomal deletions that caused the cancer and those that evolved later
on, such as during metastasis.

•

While these factors make cancer research

very difficult, they are the same reasons cancer research is so necessary .
If we learn more about one of the chromosomal deletions, it may unlock
answers to deletions on other chromosomes as well.
Since the transfer of genetic information from one generation to
another is by the transmission of chromosomes during meiosis, and there
are so many chromosomal alterations and deletions in breast cancer, it
can be hypothesized that a large amount of breast cancer develops because
of genetic inheritance .
predominantly sporadic.

This is not the case.

Only around 10% of the cases are hereditary.

(Lindblom et al., 1993)

•

In fact, breast cancer is
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•

•

•

Even though only 10% of all breast cancer cases are inherited, this
still amounts to many women inheriting breast cancer each year.

A gene

that causes a cell to take on some of the characteristics of a cancer cell
is called an oncogene. (Bishop, 1985)

Some oncogenes are introduced to

the cell by viruses, such as the Rous sarcoma virus of chickens, which can
transfer normal cells to a malignant state. (Stehlin, 1976)

However, the

Rous sarcoma virus was not originally carcinogenic, it became so only
after "kidnapping" a normal cellular gene.

This type of gene was called a

proto-oncogene by Varmus and Bishop. (Stehlin, 1976).

Proto-oncogenes

become oncogenes - and thus cause malignancy - when activated by
something else.

What activates proto-oncogenes?

Basically, anything in

the environment that can cause a mutation in the DNA.

In fact, the

carcinogenic potency of chemical compounds is directly correlated with
their mutagenic ability. (Mccann, 1975)
Why, if proto-oncogenes can be activated into oncogenes and cause
cancer, do we have them in our genetic material?

After all, about 50 of

the 50,000-100,000 genes in the human genome are proto-oncogenes.
(Weinberg, 1994)

The answer lies in the .fact that proto-oncogenes encode

many of the proteins that allow a cell to respond to growth factors.

In

other words, when a cell is informed to reproduce, proto-oncogenes are
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activated and begin churning out the materials that make cell division and
replication possible, or instruct other genes to do so.
part of cell metabolism and the cell cycle.

This is a normal

However, when a proto-

oncogene is mutated, and thus activated, they lose their ability to be
regulated - to be shut on or off by environmental cues - and thus keep
promoting cellular division.

At this point, they are oncogenes.

Often,

activation occurs by chromosome transversion, the switching of two
chromosome arms.

Such a switch sometimes places a proto-oncogene next

to a promoter, which leads to abnormal and unintended cell growth.
Robert Weinberg explains the conversion of proto-oncogene into oncogene
•

very well, • ... oncogenes are hyperactivated versions of normal cellular
growth-promoting
stimulating
ceaselessly."

genes.

signals
(1994)

into

By
a

The

releasing

cell,

strong,

oncogenes

key to

normal,

can

unrelenting
drive

healthy cell

cell

growthgrowth

growth

is

moderation, a balance between growth-promoting proto-oncogenes and the
genes that regulate cell growth.
The genes that regulate cell growth are known as anti-oncogenes, or
more commonly, tumor suppressor genes.

Like all genes, since there are

two chromosomes, there are two copies of each tumor suppressor cell.
So, even if a tumor suppressor gene is knocked out by mutation, the other

•
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can serve the function and suppress carcinogenesis.

It is only when the

second copy is knocked out that carcinogenesis arises.

This theory is

known as Knudson's hypothesis, or the atwo-hit" theory. (Knudson, 1971)
Fortunately, the chances of this happening are very small.

In fact, the

chance of losing one copy of a tumor suppressor gene is approximately 1 in
1 million; the chance of losing both copies is 1 in 1 billion per cell
generation. (Weinberg, 1994)

There are not as many known tumor

suppressor genes as proto-oncogenes.
be covered in detail in this paper.

Three tumor suppressor genes will

The first is the p53 tumor suppressor

gene on 17p, the second is the BACA 1 tumor suppressor gene on 17q, and
•

•

the third is the BRCA2 gene on 13q.

Other tumor suppressor genes that

will be mentioned only briefly are those found on 3p, 7q, and 13q.
The ·two-hit" theory is sometimes compromised.

For example, one

allele of the BRCA-1 gene is lost to a high degree in some families.

This

makes the odds of developing breast cancer substantially greater in these
individuals.

For this reason, BACA 1 is sometimes referred to as a

·familial" breast cancer gene.

As mentioned earlier, proto-oncogenes and

tumor suppressor genes both play a part in tumorigenesis.

Robert

Weinberg has a great analogy for this concept, "So, a tumor can arise by a
stuck accelerator (an activated oncogene) or a faulty brake (inactivated
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•

growth-suppressing gene).

(1994)

Tumors that arise from both are

especially dangerous.

p53

The most common tumor suppressor gene mutation associated with
human tumor formation is p53. (Hollstein et al., 1991; Trudel et al., 1992;
Weinberg, 1994)

Indeed, p53 mutations are found in DNA samples from

more than half of all human tumors.

In fact, mutations in the p53 tumor

suppressor gene are the most common changes found in breast cancer. The
incidence of mutations in this gene are 15-50%, depending on the stage of
the tumor and the method of detection. (Bartek et al., 1990; Davidoff et
al.,

1991; Osborne

et al.,

1991) On average,

p53 is mutated

approximately 30% of sporadic breast cancers. (Prosser et al., 1991)

in
p53

is located on the short arm of chromosome 17. (Fig. 11)
How do p53 mutations lead to tumorigenesis?

Basically, since it is

a tumor suppressor gene, when it is mutated, it loses its function and
tumors are free to grow.
complicated.

However, the total mechanism is somewhat more

The passage of cells through the cell cycle depends on the

activity of enzymes know as cyclin-dependent kinases, or Cdks. (Marx,
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1993)

The enzyme known as Cdk2 pushes cells out of the first phase of

the cell cycle into the DNA synthesizing phase. The p53 gene encodes tor a
protein that induces the gene that produces a 21 kilodalton protein known
as either Cip1 (Harper and Elledge, 1993), Waf1 (EI-Diery et al., 1993), or
sdi1 (Smith et al.).
inhibitor of Cdk2.

The Cip1, or Cdk-interacting protein, is a good

In other words, it acts as a brake for cellular division

by inhibiting the enzyme that pushes cells into the replication phase.
When a mutation arises in the p53 gene, the protein the gene codes for
does not work properly, and it is unable to inhibit the enzyme Cdk2.

As a

result, growth is uncontrolled . (Fig. 12)
Other research shows alternative or additional tumor suppressing
mechanisms of p53.

There are several publications documenting the

ability of p53 to actually suppress the promotor sequences of certain
oncogenes by interacting with them.

(Ginsberg et al., 1991; Santhanam et

al. , 1991; Kley et al., 1992; Mack et al., 1993)

Promoter sequences are

sections of DNA that lie before and outside a gene.

They help DNA

replication get started by providing a ·docking site" for the replication
machinery of a cell, DNA _polymerase.

Other researchers believe p53 acts

to induce apoptosis, or programmed cell death, on tumor cells that have
avoided destruction with the help of oncogenes. (Hermeking and Eick,
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1994) In any case, the normal p53 gene acts as a tumor suppressor.

When

it is mutated, it loses its function, leading to tumorigenesis.
As mentioned earlier, the majority of cancers are sporadic.

That is ,

most cases of cancer develop within the cells on their own, and are not
inherited.

Loss of the p53 gene is sporadic.

breast cancer cases.

It is not linked to familial

The Handbook of Gene Level Diagnostics in Clinical

Practice explains after thorough testing of familial breast cancer DNA,
"No structural abnormalities in the p53 genes were noted, discounting the
possibility that structural abnormalities of the p53 gene contribute to the
heritabie predisposition for the development of breast cancers." (Kovach,
1991)

More specifically, "The incidence of p53 germline mutations as a

cause of familial (Borrensen et al., 1992; Warren et al., 1992; and Prosser
et al. , 1991 ), early onset {Sidransky et al., 1992), or bilateral breast
cancer (Lidereau et al., 1992) is low, less than or equal to 1%." (Elledge et
al., 1993)
Even though p53 mutations are not found in familial breast cancer,
the fact that p53 mutations occur so often in sporadic breast cancer make
them extremely dangerous and life-threatening.

The high rate of incidence

of this mutation is not the only factor that makes it dangerous.

Patients

diagnosed with tumors that contain a p53 mutation have very poor
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prognosis . (Elledge et al., 1993)

This is due to the fact that tumors

resulting from p53 inactivation are very resistant to treatment. (Lowe et
al., 1994)

Besides being difficult to treat, once p53-induced tumors are

taken out or remedied, tumors often come back.

•43% of women with a

p53 altered tumor had a recurrence by 5 years, while only 21 % of women
without an alteration had a recurrence: (Elledge et al., 1993)

To

reiterate, p53 mutations are so life-threatening because they occur often
in tumors, p53-induced tumors are very resistant to treatment, and the
chance of recurrence in women with p53-altered breast tumors is twice
as common as women with tumors that did not contain a p53 mutation .

•

BRCA1

While the majority of breast cancer cases are sporadic, or occur
naturally, an estimated 10% are suspected to be familial, or inherited.
(Lalle et al., 1994) The tumor suppressor gene p53 appears to play no part
in the development of familial or early-onset breast cancer.

However, the

tumor suppressor gene known as BRCA 1 _has a major role in breast cancer
occurring in a familial or early-onset context, and a very minor role in
sporadic cases. (Hall et al., 1990; Futreal et al., 1994) The BRCA1 gene is
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also connected to ovarian cancer in families with a history of breast
cancer. (Narod et al., 1991)

In other words, the BACA 1 gene confers

susceptibility to breast and ovarian cancer, but is more closely linked to
The BACA 1 gene lies on the long arm of chromosome 17,

breast cancer.

around 17q11-21. (Figs. 13 & 14)

The connection of familial breast cancer

has been documented by Lindblom et al., •... tumors from breast cancer
families with early onset lost heterozygosity on 17q more than any other
tumors." (1993)

It is estimated that BACA 1 is responsible for breast

cancer in one-half of the families with multiple cases of breast cancer,
and almost all of the families with both breast and ovarian cancer in their
•

histories. (Easton et al., 1992)

BACA 1 · is estimated to be responsible for

5% of all breast cancers , but 25% of early-onset cases occurring in women
less than 30 years of age. (Claus et al., 1991)
The role of the BACA 1 tumor suppressor gene appears to be very
similar to that of the p53 tumor suppressor gene.

It is most likely BACA 1

encodes a protein that is a negative regulator of cell growth. (Miki et al. ,
1994)
protein.

Mutations in the BACA 1 gene knock out the functionality of the
In fact, Miki et al. have shown that three of the five mutations

they found

in

familial

breast tumors

were

mutations that

caused

production of the protein to cease, thus ruining the efficacy of the protein .

•
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Their work also supported the idea that the protein acts as a negative
regulator of cell growth, ·The nature of the three mutations observe9 in
the BACA-1

coding sequence is consistent with production of either

dominant-negative proteins or non-functional proteins: ( 1994)

A dominant-

negative protein is one that interferes with the job normal proteins do,
and destroy tumor-suppressing capabilities in another way.

The BACA 1

tumor suppressor gene obeys Knudson's hypothesis, or the "two-hit"
theory.

In familial breast and ovarian cases, one of the tumor suppressor

alleles is lost at birth, meaning two good copies are not received from the
parents.
•

This is why it is referred to as familial breast cancer.

With one

copy gone, it is sufficiently easier to develop cancer because i1 is much
easier to lose one allele from mutation than two. (Smith et al., 1993;
Kelsell et al., 1993)
Statistical evidence taken from families with a history of earlyonset breast and ovarian cancer support the hypothesis that the BACA 1
gene region is responsible.

Tumors studied from affected BACA 1 carriers

show loss of heterozygosity that invariably involves loss of the normal
BACA 1 allele. (Smith et al., 1992)

In one study, 50% of breast carcinomas

and 57% of ovarian carcinomas showed loss of heterozygosity in the

•

BACA 1 region, meaning loss of one BACA 1 allele.
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(Futreal et al., 1994)

•

These levels are consistent with numerous other studies .
An inherited mutation leading to loss of the BRCA 1 tumor suppr~ssor
gene is very dangerous.

Fortunately, the familial, early-onset breast

cancer disease is not completely penetrant.

Penetrance is the measure of

how many people with a gene develop the characteristic carrie.d by the
gene.

In the case of BRCA 1, penetrance is a measure of how many carriers

of a mutated BRCA 1 gene develop breast cancer.

There is a chance that

the good copy of the gene that remains in the cells will never be taken out

•

by single mutations.

As Hall et al. point out, " ... the disease is not

completely

among

penetrant

susceptible

persons,

with

expression

depending on gender, age, and non-genetic risk factors.• (1990)

First, it

appears that only women carriers of the mutated BRCA 1 gene have
increased risk.

While men do in fact get breast cancer (but much more

rarely}, BRCA1 does not appear to play a role in its development.

However,

men with the mutated BRCA 1 gene are at an increased risk of prostate
cancer, about 3.5 times greater probability than non-carriers. (Ford et al.,
1994)

Furthermore, both women and men carriers are about four times as

likely to develop cancer of the colon than non-carriers. (Ford et al., 1994)
(Fig. 15)

•

While not completely penetrant, loss of the BRCA 1 gene is still very

22

•

dangerous, especially to older women. (Figs. 16 & 17)

The probability that

a female carrier of BRCA 1 will be diagnosed with breast cance_r is
approximately 73% by age 50 and 87% by age 70. (Easton et al., 1992)
Goldgar et al. suggest the probability is 40% by age 50 and 90% by age 70.
(1994)

Hall et al. estimate the probability of developing breast cancer in

women that carry the defective gene is 37% by age 40, 66% by age 55, and
82% over the lifetime. (1990)

The probability for non-carriers is 0.4% by

age 40, 2.8% by age 55, and 8.1 % over the lifetime.

These statistics alone

are threatening, but BRCA 1 also confers an increased probability to
develop ovarian cancer, approximately 29% by age 50 and 44% by age 70.
•

•

(Ford et al., 1994)

An inherited BRCA1 mutation is severe, as a carrier

has a lifetime risk of either breast or ovarian cancer of close to 100%.
(Ford et al., 1994)

This statistic alone demands more attention be spent

to this life-threatening disease.
What explains the variable penetrance of the BRCA 1 susceptibility?
It .is largely unknown.

It is believed that mutations in BRCA 1 only cause

susceptibility to breast or ovarian cancer in certain stages of breast and
ovary development. (Futreal et al., 1994)

As mentioned earlier, the

penetrance is dependent on gender, age, and non-genetic risk factors.
variance due to gender and age have already been explained.
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The

A non-genetic

•

risk factor that determines penetrance is age of first pregnancy.

The

younger a woman is when she is pregnant for the first time, the lower her
risk for developing breast cancer.

Women whose first pregnancy occurs

after 29 years of age are twice as likely to develop breast cancer as those
women who are first pregnant before the age of 20. (Goldgar, 1994)

Also,

late age at menopause and obesity confer an increased risk of breast
cancer development. (Goldgar et al., 1994)
Recently, it has been proposed in the literature that there are two
different susceptibility alleles for the BACA 1 gene.

One confers a high

susceptibility to breast cancer and a low susceptibility to ovarian cancer,

•

and the other does just the opposite .

If present, BRCA1-alpha - confers a

breast cancer risk of 91 % by age 70 and an ovarian cancer risk of 32% by
age 70, while BACA-beta confers a 70% breast cancer risk by age 70 and
an ovarian cancer risk of 84%. (Ford et al., 1994)

Together, they confer

the 87% breast cancer risk and 44% ovarian cancer risk noted above.

The

two-subgroup hypothesis better explains the observed patterns of breast
and ovarian cancer risk.

BRCA2

•
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An even more recent development has been the proposal of another
BACA tumor suppressor gene.

While BACA 1 is most closely associated

with families that have both breast and ovarian cancer in their history,
BACA2 is responsible for most cases of male breast cancer. (Ponder,
1994)

The two are similar in the fact that they are each responsible for

one-third of the early-onset, familial breast cancer cases. (Ponder, 1994)
Together, they are responsible for two-thirds of all early-onset cases,
and slightly over 5% of all breast cancer cases. (Futreal et al. , 1994)
BACA2 does not appear to be involved with increased susceptibility to
ovarian carcinoma. (Futreal et al., 1994)
•

The gene has been localized to

chromosome 13q12-13. (Futreal et al. 1994)

Others

Several other chromosomal abnormalities have been associated with
breast cancer development.

For example, it has been suggested that there

are two tumor suppressor genes on the short arm of chromosome 3, at 1314 and 24-26. (Chen et al., 1994)

This study found loss of heterozygosity

in the first region in 41 % of the· cases and loss of heterozygosity in the

•

second region in 45% of the cases.

It was also discovered that most of the
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losses were a result of actual physical deletion of those segments of the
chromosome.
The retinoblastoma (Rb) gene is also a tumor suppressor gene.

It is

a 200 kb gene that encodes a 11 O kilodalton protein which acts as a
mediator of the cell cycle. (Croghan, 1993)

The Rb gene is thought to

achieve growth-suppressive activity by binding to a transcription factor
and inhibiting copying of the DNA. (Trudel et al., 1992)

Possibly for this

reason, tumors linked to loss of the Rb gene are quite serious, as there is
a positive correlation between Rb and large tumor size. (Spandidos et al.,
1992)
•

The gene is located at 13q14, very near the location of the newly

proposed BRCA2 gene at 13q12-13.

It is possible that some of the loss of

heterozygosity attributed to the retinoblastoma gene over the past
several years was due to the then unknown BRCA2 gene.
that the reverse is the case.

Or, it is possible

Either way, more research is necessary in

this area to determine responsibility and possible interaction between the
two tumor suppressor genes.
There also appears to be a tumor suppressor gene on chromosome
7q31. (Bieche et al., 1992)

Loss of heterozygosity in the region of 7q31

was detected in 41 % of breast tumor DNA. (Bieche et al., 1992)

Since this

is sufficiently higher than the 0-10% loss at other random regions of the

•
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DNA (Mackay et al., 1988; Bieche et al., 1990), it is a significant finding.
Patients with a mutation in the 7q31 region had a significantly higher risk
of relapse compared to patients without a 7q31 mutation (55% and 21%,
respectively).

In addition, patients with the mutation had a shorter metastasis-free and
overall survival than those without the mutation.

(Bieche et al., 1992)

The correlation between loss of the 7q31 gene and shorter metastasisfree survival leads some to believe that the gene not only serves as a
tumor suppressor gene, but as a metastasis suppressor gene as well.
(Bieche et al., 1992)

•

•

They also had a much greater mortality rate (41 % vs. 15%).

Myths

It is impossible in today's world to make it through one week, maybe
even one day, without hearing something about breast cancer.

Reports in

the press and conversations with other people barrage us with the latest
info on what causes breast cancer.

As a result, there are many myths.

However, not all of the talk is erroneous;

there are some environmental

factors that contribute to breast cancer development.
the myths .

Let us start with

First, research conclusively shows that diet does not cause
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breast cancer.

In one study, two very large experimental groups of women

were assembled, about 800 in each.
confirmed cases of breast cancer.

One group consisted of women _with
The other group consisted of women

who were determined to be free of cancer.
both in the past and present, was monitored.

The diet of the two groups,
The investigators found no

connection between the amount of total protein, total fat, saturated fat,
unsaturated fat, or total carbohydrates and increased risk of breast
cancer. (Katsouyanni et al., 1994)

In short, diet was not related to the

development of breast cancer.
The second myth that must be dispelled is the risk from surgical
•

•

implants for breast augmentation.
cancer.

Breast implants do not cause breast

One study emphasized the fact that in the seven-year period from

1973-1979, there were 34,000 women who had their implants for at least
ten years.

In the seven year period from 1980-1986, there were 343,000

women who had their implants for at least ten years.

So, in other words,

approximately ten times more women had possessed their implants for a
minimum

of ten

years

in the

second time

period

than the first.

Regardless, the total number of breast cancer cases per 100,000 women
were identical for the two time periods. (Engel, 1992)

In other words,

even though there were ten times as many women with implants, there
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was no increase in breast cancer overall.

It may be argued that, in fact,

there was an increase due to implants, but it was obscured by a decr~ase
somewhere else.

This is unlikely and even if it was likely, it would not

alter the findings to any noticeable degree.

Even if the data were

interpreted for a worse-case scenario, it would only amount to an
additional 2.8 breast cancer cases nationwide each year. (Engel, 1992)
This figure is hardly significant.

Engel sums it up quite well, ·with an

allowance of a 10-year latency period, the data did not reveal an effect on
breast sarcoma

incidence from

the

increased

frequency

of

breast

implantation procedures." (1992)

•

One myth that has some degree of truth concerns the · intake of
alcohol on breast cancer development.

In one study, people who drank

more than three drinks per day were 3 times more likely to develop breast
cancer, while those who drank more than four drinks were almost four
times as likely. (Katsouyanni et al., 1994)
have an elevated risk.

More moderate drinkers did not

Also, the amount of consumption had less to do

with cancer development than the frequency of drinking.

In any case, high

levels of alcohol consumption are associated with higher breast cancer
risk while diet and breast implants are not.

•
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Experimental-

The presence of oncogenes and the loss of tumor suppressor genes in
the tumor tissue of women who had undergone prophylactic mastectomy
sugary at the

Mayo Clinic was studied.

Since many prophylactic

mastectomies have been performed at the Mayo Clinic, there is an
extremely large amount of material from many patients on which the
study was based.
and

tumor

My role in the study consisted of examining the normal

breast

tissue

of

sixteen

women

who

had

prophylactic

mastectomies at the Mayo Clinic for loss of the tumor suppressor genes
•

•

p53 and BACA 1.

Methods-

For each patient, two paraffin blocks containing tissue samples
were obtained from tissue registry.

One block contained tissue from the

cancerous breast and one block contained tissue from the non-cancerous
breast.

4 um sections were cut from the blocks using a Leica-Jung

RM2025 microtome.

Sections were mounted on five acetate microscope

slides and six sterile glass microscope slides.
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The first and last sections

•

were each mounted on glass and placed in a 62oC drying oven to melt the
paraffin and make the sections adhere to the slides.

The slides were Jhen

stained with hematoxylin and eosin to be used by the pathologist to insure
cancerous tissue was present. (Fig. 18)

These areas were marked .

By

examining the first and last sections taken from the paraffin block, the
pathologist confirmed that we were using tissue of the appropriate type
in each trial.
The acetate sheets were used for cancerous and non-cancerous DNA
acquisition.

First, the slides were placed in Histo-Clear for ten minutes.

The areas the pathologist had indicated on the glass slides as being

•

•

cancerous and non-cancerous tissue were excised out of the acetate slides
using a sterile scalpel.

The pieces of tissue-coated acetate were placed

in 1.5 ml screw-top Sarstedt ubes that had been sterilized in a Fisher UV
Crosslinker for 1O minutes.

The DNA was digested off the slides by

placing 2 ul of Protease K (20 mg/ml) and 100 ul of DNA Paraffin
Extraction Buffer (100 mM Tris HCI, 2 mM EDTA, pH 8) in each tube.
were then incubated in a 370c shaker overnight.

They

After the DNA was

completely dissolved, the tubes were boiled for ten minutes to destroy the
activity of the Protease K.
Polymerase Chain Reaction (PCR) was then used to amplify the DNA
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of each sample.

The reaction mixture contained six main substances .

First, 2.0 ul of patient DNA was used as the template in the amplificaJion.
Second, 3.0 ul of PCR buffer (containing 200 uM of each deoxynucleotide
except

cytosine,

Mg2+, and Tris buffer), was added to maintain the

reaction and provide the materials for replication.

Third, 0.1

ul of

forward primer and 0.1 ul of reverse primer were used.

Primers anneal to

specific sites on a DNA strand and provide a spot to begin DNA replication.
Where a primer anneals depends on its base sequence.

(Fig. 19)

So by

choosing the base sequence of a polymer, the area amplified can be
controlled.
•

In this manner, one can amplify only the part of the genome

that contains the gene to be studied.

So, to study the loss of p53 and

BRCA1, primers (we·senba.ch) flanking the areas where these genes are
found were used.

The primers used for the gene p53 were D17S786 and

D17S807, which cover areas on chromosome 17p. The primers used for the
BRCA1

gene were

chromosome 17q.

D17S796 and D17S250, which cover areas on

Fourth, 0.1 ul of Taq DNA polymerase, the enzyme that

polymerizes, or connects, the deoxynucleotides in the correct sequence to
match the

template

DNA,

was

added.

Fifth,

0.1

ul

of cytosine

radioactively labeled with 32P (produces beta particles) was added for
imaging purposes. Sixth, the remainder of the reaction mixture consisted

•
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of water, to bring the total volume up to 15 ul (9.7 ul of water).

In two

cases, 4.0 ul of template DNA was needed for good results, so the water
was adjusted to 8.7 ul.
The reaction mixtures were then placed in 0.5 ml Thin-Walled
GeneAmp Reaction Tubes by Perkin-Elmer.
in an Ericomp Thermal Cycler.

The reaction was run at 95oC for 1 minute,

55oC for 2 minutes, then 72oC for 1 minute.
times.

These tubes were then placed

This cycle was completed 35

Then, the tubes were incubated at 72oC for 10 minutes, and then

maintained at room temperature.

The purpose of the 95oC step was to

denature the DNA, or separate the two coiled strands of polymerized
•

The 550c step anneals the primers to the ·separated

deoxynucleotides.
strands of DNA.

The purpose of the 72oC step is to elongate the newly·

forming strands of DNA. (Fig. 20)

72oC is an optimal temperature for Taq

polymerase to function, hence, keeping the reaction at this temperature
synthesizes the DNA the fastest.

The cycle is then repeated, only this

time, there are four strands of DNA after the denaturing step.

Therefore,

primers attach to four strands and four new strands are started during the
elongation phase.

This is repeated again and again, for a total of 35

times, each time the number of strands growing geometrically (2, 4, 8, 16,

•

32, 64, 128, 256, ... )

The final 72 degree step allows time for all the new
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strands to continue synthesizing to the end of the strand.
of PCR, there are 1225 strands of DNA. (Fig. 21)

After 35 cycles

This is the central tenet

of Polymerase Chain Reaction, it is a chain reaction.

For this reason, it

takes little time to greatly amplify the amount of DNA.

As a result, many

scientific trials can be conducted off a very small amount of tissue. T h e
success of PCR is very well documented. However, the success of PCR on
DNA from paraffin-embedded tissue is not as high as DNA from fresh
blood, but it still is adequate and attainable. (Wright and Manos, 1990;
Bowcock et al. , 1993; Chamberlain et al., 1993)
To analyze the DNA, polyacrylamide gel electrophoresis (PAGE) was
•

completed.

PAGE is a technique used to separate linear polymers on the

basis of their size.

Polyacrylamide , when it is mixed with ammonium

persulfate and TEMED, forms a mesh gel.

An electric field is then applied

to the gel via electrodes in a buffer solution.

Since DNA is negatively

charged, it will migrate from the negative to the positive electrode , as
opposite charges attract.

Smaller fragments move more quickly through

the gel than larger fragments, as the larger fragments have more
difficulty fitting through the spaces in the mesh gel. This allows one to
separate the fragments according to molecular weight.

•

The gel was made by pouring a mix of 6% polyacrylamide (19:1
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acrylamide : bisacrylamide), 7% urea, 1% ammonium persulfate {APS - 550
ul of 10%), and 0.5 X TBE buffer between two glass plates.

This buffer

was made with 0.045 M Tris-Borate (54 g Tris base, 27 .5 g boric acid) and
0.001 M EDTA (pH 8.0).
samples.

After the gel had set, it was loaded with the DNA

Before they were loaded, a loading buffer was added (98%

deionized formamide, 10 mM EDTA, 0.025% xylene cyanol FF, and 0.025
bromophenol blue).

The loading buffer had three purposes.

First, it

increased the density of each sample, making it easier to load the sample
into the wells in the gel.
process.
•

Second, it added color, simplifying the loading

Third, the buffer contains dyes that migrate at predictable rates

through a gel placed in an electric field.

Therefore, it was possible to

estimate the location of the DNA fragments by judging where the dyes
were in the gel.
There are primarily two dyes in the loading buffer, a teal green and a
deep blue.
weight.

The molecules that make up each dye have a certain molecular

Each molecular weight can be translated into an approximate

base-pair range.

The teal green dye runs with about 120 base-pair

fragments, while the deep blue runs with 150-155 base-pair fragments.
Since the primers amplify alleles of 114-170 base-pairs, the green dye

•

was run to about two inches from the bottom of the gel in a Fisher
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Scientific FB-Seq-3545 Sequencing System connected to a power supply
set at 3000 V, 75.0 W, and 200.0 mA.

Next, the gels were disconnected

and transferred to paper and dried on gel dryers for approximately 1.5
hours.

Once the gels were dry, they were placed in autoradiography

intensifying film cassettes with a single piece of Kodak X-OMAT AR
Imaging Film (35 X 43 cm).
temperature.

The film was exposed overnight at room

If the radioactive signal was very weak, the film was

exposed overnight at -75oC.

After being exposed, the film was developed
All film work was completed in a

using a Kodak X-OMAT developer.
darkroom.

•

As explained earlier, the primers used in the PCR were designed to
anneal to the areas of the chromosome where the tumor suppressor genes
p53 and BRCA 1 are found.

So, the radioactively-labeled fragments on the

gel contained the section of DNA containing the p53 or BRCA 1 genes.

Loss

of heterozygosity was used to determine absence of these two genes.

Only

heterozygous individuals, or those with two slightly different alleles for
each gene, could be used for this method.

A heterozygotic sample will

show two bands of DNA on the film, as different alleles of the same gene
have

•

slightly

different

lengths.

By

comparing

a

set

of

normal

heterozygous alleles from non-cancerous breast tissue to the alleles
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obtained from cancerous breast tissue, it is possible to determine loss of
heterozygosity in the cancerous tissue.

Loss of heterozygosity is

apparent when, for example, the top alleles are of near identical intensity
in the normal and tumor tissue, while the bottom allele of the tumor
tissue is much lighter, or less intense, than the normal tissue. (Fig. 22)
When a allele is lighter, it has less radioactive label, and hence less DNA.
Since the PCR conditions were the same for both types of tissue, there
should be the same amount of DNA. Less DNA suggests loss of the allele in
the tumor tissue for some reason.

When the loss of DNA is in the p53 or

BACA 1 regions, a loss of that tumor suppressor gene is indicated.
Therefore, in effect, we were looking for lighter tumor suppressor gene
bands in the cancerous tissue than in the non-cancerous tissue.

If the

tumor suppressor genes were lost in the cancerous tissue when they were
not in the non-cancerous tissue, there is a good possibility they were
responsible for, or associated with, the development of the cancer.

Results-

The primers D17S796 and D17S786 were used to detect loss of
heterozygosity of p53. (Fig. 23)

In the region amplified by the primer
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D17S796, loss of heterozygosity was detected in patients 1 and 11.
Patients 7 and 8 were heterozygous with no loss.

Loss could not be

determined in patients 6, 12, and 15 because of homozygosity in the
region.

Loss could not accurately be determined in patients 2, 3, 4, 5, 9,

1O, 13, 14, and 16.

In the region amplified by the primer D17S786, loss of

heterozygosity was detected in patients 1, 2, 6, 9, 11, and 15.
was once again heterozygous with no loss.

Patient 7

Loss of heterozygosity could

not be determined in patients 3, 5, 12, and 14 because of homozygosity.
Loss could not be ascertained on patients 4, 8, 10, 13, and 16.
To detect loss of heterozygosity in the region containing BACA 1, the
primers D17S250 and D17S807 were implemented. (Fig. 23)

Patients 1

and 9 showed loss of heterozygosity in the region flanked by primer
D17S250.

No loss was detected in patients 5, 14, and 15.

7, 11, and 12 were homozygous.
3, 8, 10, 13 and 16.

Patients 2, 4, 6,

Loss could not be determined in patients

The region amplified by the primer D17S807 showed

loss of heterozygosity in patients 1, 4, 6, 8, 9, and 12.
and 15 showed no loss in the region.

Patients 2, 7, 14,

Loss of heterozygosity could not be

determined in patients 3, 5, 11, and 16 due to homozygosity.

Patients 10

and 13 could not be determined. (Fig. 24)
Excluding indeterminate trials, the region amplified by D17S796
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showed loss of heterozygosity in 28.6% of patients, no loss in 28.6% of
patients, and 42.9% of the patients homozygous.

In the region ampl_ified

by D17S786, 54.5% of the patients showed loss of heterozygosity, 36.4%
showed no loss, and 9.1 % were homozygous.

Considering both primers, the

short arm of chromosome 17, where p53 is located, showed loss of
heterozygosity in 44.4% of patients, no loss in 33.3% of patients, and
22.2% of the patients homozygous.
Also ignoring indeterminate trials, the region flanked by D17S250
showed loss of heterozygosity in 18.2% of patients, no loss in 27 .3% of
patients, and 54.5% of the patients homozygous.

The region amplified by

D17S807 showed 42.9% of the patients had lost one of the heterozygotic
alleles, 28.6% had no loss, and 28 .6% were homozygous.

When both.

primers are cons·dered, the long arm of chromosome 17, containing
BACA 1, showed loss of heterozygosity in 32% of patients, no loss in 28%,
and 40% of the patients were homozygous and could not be detected.
In patients purely heterozygous in the region of interest, 50%
showed loss in the region amplified by D17S796.

The region amplified by

D17S786 showed loss in 60% of heterozygous patients.

In the region

amplified by D17S250, 40% of the heterozygous individuals showed loss,
while 60% of the heterozygous patients showed loss in the D 17S807
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region.
In summary, the region on 17p containing p53 showed loss in 5'? .1 %
of heterozygous patients.

The BACA 1-containing region on 17q showed

loss in 53.3% of heterozygous patients. (Fig. 25)

Discussion-

It was very unfortunate that the results of some of the trials were
indeterminate.

Even

after many repetitions

with

concentrations, some trials remained inconclusive.
•

•

different

reaction

In the same fashion,

.the fact that some patients were homozygous in the amplified regions
created problems, since homozygous individuals cannot be analyzed by
PAGE.

Because this possibility was known before the experiment was

begun, primers with high HET scores were used.
the

probability of

amplified region.

heterozygosity of the

The HET score expresses

general

population

in the

The value is expressed as a decimal between O and 1.

The decimal can be converted into a percentage.

For example , primer

017S796 has a published HET score of 0.824. (Weisenbach)

This indicates

that a given sample will be heterozygous in the amplified region 82.4% of
the time.

In

other words,

82.4% of the population
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is estimated

•

heterozygous in the region.

This is a good HET score; primers with HET

scores lower than 0.65 would not be very useful for this study.

Even

though the HET scores were pretty high (0.773-0.862), some patients were
still homozygous and unreadable in terms of loss of heterozygosity.
When indeterminate and homozygous trials were discarded, the
observed loss of heterozygosity of the region containing p53 was very
close to the expected loss.

As mentioned earlier, p53 is mutated in 50%

of all cancers. (Weinberg, 1994)

More specifically, it is mutated in 15% of

in situ cases and around 50% of serious cases. (Bartek et al., 1990;
Davidoff et al., 1991 ; Osborne et al., 1991)
•

our study matches this very closely.

The observed value of 57% in

As mentioned earlier, thete were a

number of indeterminate trials, 14 of 32 to be exact.

If the indeterminate

trials were more conclusive, we might see an even closer match.

The

observed HET scores of the p53-containing fragments were extremely
close to the HET scores suggested by the manufacturer.

The average

observed HET score was 0.777 compared to the average reported value of
0.793.

So, additional trials to lower the number of homozygous trials

would be unprofitable unless a different primer was used.

Even so, the

number of readable trials would not increase noticeably, and other

•

complications may develop .
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The results of the BACA 1 trials do not appear as accurate as those
of the p53 trials.

The region containing BACA 1 was mutated in 53% of_the

heterozygous individuals.

This is sufficiently higher than the reports

estimating that BACA 1 is mutated in 5-10% of all breast cancer cases.
This discrepancy can be explained by four main theories.
trial were indeterminate.

First, 7 of 32

It is possible that all of these trials show no

loss of heterozygosity; this would bring down its percentage.

On the other

hand, it is also possible that all indeterminate cases would show no loss.
Both of these situations are unlikely; it is most likely that some trials
show loss and others show no loss
•

•

However, either one may · have a

greater chance to have complications that prevent accurate determination.
This is impossible to accurately determine in my study, so we must be
satisfied with the possibility that some error may have arisen from
indeterminate trials.
Second, the number of homozygotic individuals was much higher than
expected.

Using the manufacturers' reports, we calculated a HET score of

0.839 for the two primers combined , after the indeterminate trials were
discarded.

However, the observed HET score for the two primers used for

BACA 1 amplification was 0.60.

Indeed, we observed 6 more homozygous

individuals than was expected.

If we had observed more heterozygous
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individuals, we may have detected more individuals with no loss , and
achieved more expected results.
Third, because loss of heterozygosity was examined in this study, it
is possible that we inadvertently determined more trials showing loss
when they were, in fact, not showing loss.

This situation is always

possible when dealing with results such as the intensity of bands on
autoradiography film .

The distinction between loss and no loss is very

minute and errors are possible.

The fact that we looked for loss of

heterozygosi~y may hav€ causod us to "lean" to loss when the call was
close .
•

Use o1 intensity-detecting computer software such as IMAGE may

aid in more effectively judging loss of heterozygosity in further trials.
However, the fac t at p53 showed no major discrepancies suggests that
the determinatio n of loss of heterozygosity was quite accurate.
inadvertent favoritism

was

present

in

determination

of the

results, it should havo been noticeable in the p53 results .

If

BACA 1

It was not.

Therefore , it is likely the loss of heterozygosity results are accurate in
both the p53 and BACA 1 trials.
Fourth , the discrepancy may have been caused by the characteristics
of the group studied.

•

It was mentioned earlier that 50% of early-onset,

familial cases of breast cancer showed a BACA 1 mutation. (Futreal et al. ,
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1994)

Since women with early-onset, familial breast cancer are the most

likely to have prophylactic mastectomies, it is more likely that tt:iese
women carry the BACA 1 mutation .

Indeed, we observed BACA 1 mutations

in 53% of the women in our study, which very closely matches the report
suggesting 50% of early-onset, familial cases have a BACA 1 mutation.
This suggests that the loss of BACA 1 results are accurate.

Conclusions-

It has been shown that 57% of women had lost the p53 tumor
suppressor gene in the cancerous breast tissue removed during normal and
prophylactic mastectomy surgeries.

Furthermore, 53% of these women

had lost the BACA 1 tumor suppressor gene in the same cancerous tissue.
These

results

closely

correlate

with

literature

suggesting

p53

is

commonly mutated in cancers, especially those of serious grade in the
breast.

The results also agree with reports suggesting BACA 1 is

commonly mutated in familial , early-onset breast cancer cases.
All of the following risk factors: serious tumor grade, early age of
diagnosis, and history of cancer, especially of the breast, make patients
good candidates for prophylactic mastectomy surgery.
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These same risk

•

factors are characteristics of genetic susceptibility to breast cancer.
is

known

that

recurrence.

genetic

susceptibility

increases the

risk

of

It

cancer

However, until this study, there has been no concrete evidence

of a connection between perceived high risk of recurrence, and therefore
prophylactic
susceptibility.

mastectomy

surgery,

and

actual

genetic

proof

of

In other words, it has never been determined that the

women who were having prophylactic mastectomies had genetic material
that made them get cancer.

This study has shown that women who have

had prophylactic mastectomy surgery have greater genetic susceptibility
to breast cancer development than other women .

•

More

importantly,

this

study

has

shown

that

prophylactic

mastectomy surgery is a viable and worthwhile treatment to prevent
breast cancer recurrence.

It is hoped that this information will increase

the knowledge of breast cancer.

For the same reason, this paper has

attempted to explain what cancer is while describing how the genetics of
a person cause or contribute to its development. Most of all, it is hoped
that this paper will emphasize the severity of this disease in the United
States today and tomorrow .

•
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Fig.

1

Table 1. Magnitude of the Breast Cancei;,?roblem•
Year and
percentage
change

1970
1980
1990
Percentage change

Cases

Deaths

Incidence
rate

69,000
109,000
150,000
117.4

30,000
36,000
44,000
46.7

79.9
85 .2
102.0
27:J',

Mortality
rate

26.6
26.4
27.3
2.6

• Rates are age adjusted to the I 970 population. Data from Mil~er A, Ries LAG,
Hankey BF, Kosary CL, Harris A, Devesa 55, Edwards BK, edito . SEER Cancer
Statistics Review: 1973-1990. Bethesda, MD: National Cane Institute, 1993.
NIH Publication No. 93-2789; and American Cancer Society. Cancer facts and
figures-I 994 . American Cancer Society, Inc., 1994. Publication No. 5008.94.

Sondik et al., 1994 •
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Fig. 2
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Figure 3. Breast cancer incidence, age-adjusted to
population.
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Table 2. Breast Cancer Incidence and.Mortality Rates per
100,000 Women for Black and White Women, 1989
Incidence (age)

•

Mortality (age)
All

All

Race

<50

50+

ages

<50

50+

ages

Whites
Blacks
All races

32.2
30.9
31.6

346.2
263 .5
333.4

109.1
87.8
105.5

5.9
9.2
6.2

93.9
96.0
93.1

27.5
30.4
27.5

Oat.i from Miller BA, Ries LAG, Hankey BF, Kosary CL, Harris A, Oevesa 55,
Edwards BK, editors. SEER C.mcer Statistics Review: 1973-1990. Bethesda,
MO: National Cancer Institute. 1993. NIH Publication No. 93-2789.
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Table 3. Percentage Change in Breast Cancer Incidence
and Mortality Rates for Black and White Women,
1973-1989
Incidence (age)

All

All

·'

<50

50+

ages

<50

50+

ages

-16.1
19.3
. 9.3

36.9
31.0
.,34.7

30.0
27.6
28.0

-13.2
3.4
-11.4

4.7
20.3
5.3

1.5
15.6
2.2

Race

Whites
Blacks
All races

Mortality (age)

Data from Miller BA, Ries LAG, Hankey BF, Kosary CL, Harris A, Oevesa 55,
Edwards BK, editors. SEER Cancer Statistics Review: 1973-1990. Bethesda,
MO: National Cancer Institute, 1993. NIH Publication No. 93-2789 .

•

Sondik et al., 1994.

Fig. 4

Fig. 6
Whites

Fig. 5

Whites

c50

50-54
55-59
60-64
65•

-

Blacks

.

<50
50-54
55-59
60-64
65+

Blacks ..

.

•50
50-54
55-59
60-64
65•
All Women

,so
50-54
55-59
60-64
65•

'

10

20

30

40

Percent Change
•

.:;.c,;a'

...

All Races

0

-

<50
50-54
55-59
60-64
65+

re 2. Changes in breast cancer incidence, 1973-1989, ageadjusted rates.

Sondik et al., 1994.

50

<50
50-54
55-59
60-64
65+
-20

-10

0

10

20

Percent Change

Figure 5. Changes in breast cancer mortality, 1973 -1989, agead justed rates.
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Fig. 7
Table 4. Changes in Breast Cancer Survival:
5-Year Relative Survival
Year

Whites

Blacks

1960-1963
1970-1973
1974-1976
1977-1979
1980-1982
1983-19_88

63.0
68.0
74.8
75 .1
76.7
79.3

46.0
51.0
62.9
62.5
65 .6
62.1

Data from Miller BA. Ries LAG. Hankey BF, Kosary CL. Harris A, Devesa SS,
Edwards BK, editors. SEER Cancer Statistics Review: 1973-1990. Bethesda,
MD: National Cancer Institute, 1993. NIH Publication No. 93-2789, and the
National Cancer Institute.

Sondik et al., 1994.

Fig. Ba - See next page •
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Fig. 8b
Breast Cancer Trends/Sondik
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Figure 4. Breast cancer incidence by stage at detection. age-adju~ted
to 1970.
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Fig. Ba - A scanning electron micrograph of blood vessel systems
before and after wounding. The picture on the left is before
wounding, while the picture on the right is 60 hours after wounding.
Note the extent of increased blood vessel formation, known as
angiogenesis. While in wounding angiogenesis is used to speed ·the
healing process, tumors release factors to promote angiogenesis
so that a greater amount of nutrients are carried to the area of
the tumor. This allows the tumor to grow beyond the normal parameters
imposed by the body.
(Alberts et al., 1989)

control

60 hou11 lfter wounding
100 µm

L-1
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Fig. 9a - The double-helix structure of deoxyribonucleic acid,
or DNA. The complementary base-pair interactions lie in the interior
of the two strands.
(Sherwood, 1993)
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(b)

(
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Sugar-phosphate backbone

•

•

•

Fig. 9b - The polynucleotide aspect of DNA. Each nucleotide in a
strand is composed of three parts: (1) a nitrogenous base, either
adenine(A), guanine(G), cytosine(C), or thymine(T); (2) a five
carbon sugar, or ribose; and (3) a phosphate group that forms a
phosphodiester bond with the sugar of another nucleotide, which
forms the chain. The bases are arranged to the interior of the
double helix, where they interact with bases of the other strand.
(Sherwood, 1993)

Fig. 9c - Levels of organization of DNA. The DNA chain is wrapped
around proteins known as histones, which then fold further and begin
supercoiling into chromatin, the substance which makes up the
chromosomes in the nucleus of the cell.
(Sherwood, 1993)
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•

•

•

•

•

Fig.9d - An electron micrograph of a chromosome. The centromere
can be seen near the center of the structure. The shorter end i s
known as the "p" arm, while the longer end is known as the "q" arm.
(Sherwood, 1993)

•

Fig. 9e - Transfer of information from DNA to protein. The nucleotide
sequence in DNA specifies the sequence of amino acids in a polypeptide.
One strand of the normally two-stranded DNA chain is used to form a
mRNA templated for the buildong of the polypeptide chain. Each three
nucleotide sequence in the mRNA strand codes for one amino acid in the
ploypeptide chain. The amino acid structure dictates the threedimensional shape of the protein.
(Zubay, 1993)
·
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*Thym ine [I] in DNA becomes uracil IY] in RNA .
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Chromosome: Sq
Alteration: Loss
Gene: APC

Normal
epithelium

l

12p
Activation
KRAS

•l

18q
Loss
DCC?

17p
Loss
p53

DNA llypomethylation

Hyperprolif.
epithelium

Early
adenoma

Other alterations

Intermediate
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Late
adenoma

Carcinoma

Meta,tasis

Fig. 9f - Chromosomal loss in the progression of human cancer,
from normal epithelial cells to metastasis. (Weinberg, 1994)
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Fig. 10 - Autoradiography exposure showing ~03s of heterozygosity
(LOH) in the tumor DNA of a patient. DNA from - normal breast tissue
is labeled B, while DNA from a breasi tumor is labeled T. Patient
12 is heterozygous for the amplified allele. Notice intensity
between the bottom two bands in the two samples is identical, while
the top band of the tumor DNA is much lighter in intensity than the
normal breast DNA. This is indicative of loss of a chromosomal
segment or gene.
(Lal le et al., 1994)
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Fig. 11 - Chromosome 17 and the location of p53 •
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What p53 does. When
the p53 protein is made,
it turns on the gene for a
21 kilodalton protein that
blocks Cdk enzymes,
and thus cell division.

I

,.
,.I

-1-

DNA synthesis

Cell division

•

Fig. 12 - Inhibition of cell division by
the normal p53 gene.
(Marx, 1993)

•

Fig. I. Pauems of Al ar I I loci
on chromosome 17 in individual
infonna1ive rumors (left ) or at i
five regions in groups of rumors :
with similar Al pa!!em (right).
The sizes of these groups are in dicared as percen1:1ges of the total
sample number. The remaining
1
21 'k- of the tumors not shown
(but 12 of which are shown to the
left in the figure ) had various
combinations of Al on both
chromosomal :inns . • = Al: 0 =
no Al : ¢=not infonnarive or not
an:liyzed: • = Al probably due 10
increased THRA I copy number.
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Fig. 1 3

Chromosome 1 7 and the location of BRCA1.
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Fig. 14 - Location of t he BRCA1 locus on 17g.
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Fig. 1. Schematic map of human chromosome
17. The pertinent region containing BRCA 1 is expanded to indicate the relative positions of two
previously identified genes, CA 125 (34 ) and
RNU2 (45 ). 017S855 is located within BRCA 1.

(Miki et al., 1994)
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Fig. 15 - Risks of cancer in BRCA1 carriers
compared to non-carriers. (Ford et al., 1994)
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Table 2: Risks of cancer other than breast and ovarian cancer In
17q-llnked families
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Fig. 16 - Penetra~ce
of BRCA1 at
increasing age •
(Goldgar et al.,
1994)
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Fig. 2. Estimates of penetrance. Each
graph represents cumulative risk of developing breast or ovarian cancer as a
function of age. Dashed line : log-normal
fit to data from known and possible gene
carriers in K2082 ; solid line: Kaplan~ ier step function estimate using data
from K2082 known BRCA 1 carriers only;
dotted line: penetrance estimates from
BCLC data set (3) .
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Fig. 17 - Four BRCA1-containing family pedigrees showing the
severity of BRCA1 in the development of breast cancer. Squares
represent males, circles represent females, darkened shapes
represent those diagnosed with breast cancer, slashes indicate
other types of cancer.
(Hall et al., 1990)
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Fig. 18 - Hematoxylin and Eosin (H&E) Staining Protocol
for Tissue Sections on Glass Slides

Chemical

I.i..mil

1

Xylene

10 min.

2

Methanol

10 dips

3

50% EtOH

10 dips

Hematoxylin

4 min.

~

4

5

•

HCl in Alcohol

10 dips

6

70% EtOH

10 dips

7

NH,OH in E tOH

30 sec .

8

95% EtOH

10 dips

Eosin

25 dips

10

Methanol

10 dips

11

·Methanol

10 dips

12

Xylene

10 dips

9

Apply 2 drops "Tissue Tek Coverslipping Resin" and cover slip .
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• • Primer Design:

Cig,G->T

5'ACCGACTAGA------CGGTGGAATT 3'
3'TGGCTGATCT
GCCACCTTAA 5'

5 'ACCGACTAGA - - - - - - CGGTGGAATT 3 '
GCAACCTTAA 5'
3'TGGCTGATCT - - - - - - GCCTCCTTAA 5
...
5'ACCGACTAGA
1

Fig. 19 - Designing primers to anneal to certain regions of DNA
in order to amplify a single region, or gene. Primers act as a
starting point for DNA polymerase.
(S. Volchenboum, 1994)
5·- - - - - 3 ·

s·- - - - - 3 '
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Extend

n·c
5'-3'
3'

5'

...

------3'
-------s·

S'
3'

Fig. 20 - The "thermal cycle" aspect of PCR. Each temperature
accomplishes one aspect of the polymerization.
(Volchenboum, 1994)
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After N rounds of
PCR, there are N2
copies but only
N+2 non-mutated
strands.

Fig. 21 - The "chain ,_-::.::ct ion" element of PCR. The number of
amplified fragments grows 2.t a gr->om<?tric rate. (Volchenboum, 1994)

3
5

Fig. 22
Bands of normal and tumor DNA on a polyacrylamide gel.
DNA from normal breast tissue is marked with a N, while DNA from
tumor breast tissue is marked with a T. Patients that are
heterozygous with no loss are marked H/N, while patients that are
heterozygous with loss are marked H/L. Three different primers
are shown: D6S265, D6S260, and D17S796 (p53 region). Patients 5
and 16 are H/N, while patient 5 shows loss of the region amplified
by D17S796, consistent with loss of the tumor suppressor gene p53 •
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Primers for Prophylactic Mastectomy Study

•

•

•

Primer

Map Location

Ref

Allele Range

HET

017S849
017S796
017S786
017S804
017S799
017S783
017S788
017S807
0175785
017S784
017S250/Mfd15

17pter-p13.3
17p13.3-p11.2
17p13.3-p11.2
17p13.3-p11.2
17p13.3-p11.2
17p11.2-q12
17Q11 .2-qter
17q11.2-Qter
17q11.2-qter
17q11.2-qter
17q11.2-Q12

GOB 7/28/94-default
GOB 7/28/94-default
GOB 7/28/94-default
GOB 7/28/94-default
GOB 7/28/94-default
GOB 7/28/94-default
GOB 7/28/94-default
GOB 7/28/94-default
GOB 7/28/94-default
GOB 7/28/94-default
GOB 7/21/94

251-261
144-174
135-157
156-170
186-200
241-255
186-19
114-138
181-207
226-238
151-169

0.676
0.824
0.773
0.624
0.694
0.713
0.703
0.862
0.839
0.786
81

013S171
013S176
013S166
013S162
013S158
013S159

13q12.3-Q13
13q12.3-q31
13q12.3-q31
13q21.2-Q31
13q32-q33
13Q32

GOB 7/21/94
GOB 7/21/94-default
GOB 7/21/94-default
GOB 7/21/94
GOB 7/21/94
GOB 7/21/94

227-241
211-227
115-125
182-202
99-113
169-203

0.727
0.802
0.757
0.864
· 0.823
0.906

SPN
016S265/Mfd23
016S413

16q11.2
16q21
16Q24.3

GOB 7/22/94
GOB 7/21/94
GOB 7/21/94

145-185
89-117
131-149

0.96
0.75
0.846

0115902

11p15-p13

GOB 7/22/94

145-163

0.805

INT-2
011S35
Mfd69/C030

11q13
11Q22
11Q23.3

P(?lymeropoulos,M., e
GDB 7/22/94
GOB 7/2.2/94

161-177
152-162
85-99

0.846
0.88
0.69

06S286
06S268
065308
06S264

6q16.3-Q21
6q16.3-q21
6q16.3-q27
6q25.2-q27

7/22/94
7/22/94
7/22/94
7/22/94

206-232
86-100
193-203
108-122

0.792
0.754
0.752
0.709

03S1283
03S1289
03S1261

3p25-p24.2
3p21.2-p21.1
3p14-p12

GOB 7/22/94
GOB 7/22/94
GOB 7/22/94

150-160
197-215
185-217

0.71
0.818
0.853

02S119
02S123
C08A

2p23-p15
2p
2p12

GOB 7/22/94

0.81
0.773

GOB 7/22/94

214-232
197-227
138-170

01S243
01S233
01S162

1pter-p34
1p36-p22
1p36-p22

GOB 7/28/94-default
GOB 7/28/94-default
GOB 7/28/94-default

142-170
102-132
134

0.874
0.852
0.91

GOB
GOB
GCB
GOB

Fig. 23 - A list of primers that have been or will be used in
the prophylactic masectomy study at the Mayo Clinic. Four of
the · primers, D17S796, D17S786, D17S250, and D17S807, were used
in my portion of the project; (K. DeLacey, 1994)
Page 1
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202
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1771 r.771
(.!A tGd
205

211

o·

D17S250

(0.81)

D17S807
(0.862)

220

& udy #
-25.2
25.3-

D

Homozygous

II

Heterozygous i Loss

~

Heterozygous I Normal

-

Indeterminate

F i g. 24 - Resu l ts of the study. At left
i s a g raphic showing the various markers
on chromosome 17. The four primers used
in the study are shown on the right, in
t he r egi ons where they anneal. The sixteen
patients us~d in the study are listed
horizontally. The boxes above show the
results of the loss of heterozygosity
studies, according to the key at left.
HET scores of the primers are listed under
each primer.

•

•

•

Loss of Heterozygosity Results

p53

H/L

HIN

Homoz~gous

D17S796
Patients
Percent Exe. Ind.
Percent Exe. Hom.

1, 11
28.6
50

7, 8
28.6
50

6, 12,15
42.9

D17S786
Patients
Percent Exe. Ind.
Percent Exe. Hom.

1,2,6,9, 11, 15
54 .5
60

7
36.4
40

3,5,12,15
9.1

I

Indeterminate

I

12,3,4,5,9,10, 13, 14,15
I

4,8,10,13,16

•

BRCA1
D17S250
Patients
Percent Exe. Ind.
Percent Exe. Hom.

1,9
18.2
40

5,14,15
27.3
60

2,4,6,7, 11, 12
54.5

D17S807
Patients
Percent Exe. Ind.
Percent Exe. Hom.

1,4,6,8,9,12
42.9
60

2,7,14,15
28.6
40

3,5,11,16
28.6

Total p53

0.571

Total BRCA1

0.53~

---

'

3,8,10,13,16

10,13

0 .429

--

0.467

Fig. 25 - Allelic scoring for the sixteen prophylactic masectomy
patients in the st udy . H/ L corresponds to heterozygous/loss,
H/N corresponds to heteroz ygous/no loss . The two tumo r suppressor
genes studied and the corresponding primers are listed in the
left-hand column. Patient s f i tting into each category are listed
by their study number. Percent loss of heterozygote individuals
for each tumor suppressor gene is listed at the bottom of the table .
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